Henry H Cheng1, Satish K Rajagopal2, Arnold J Sansevere3, Erica McDavitt1, Daniel Wigmore1, Jessica Mecklosky1, Kristofer Andren1, Kathryn A Williams4, Amy Danehy5, Janet S Soul6. 1. Department of Cardiology, Boston Children's Hospital, United States. 2. Department of Pediatrics, University of California, San Francisco, United States. 3. Department of Neurology, Boston Children's Hospital, United States. 4. Department of Biostatistics and Research Design Core, Boston Children's Hospital, United States. 5. Department of Radiology, Boston Children's Hospital, United States. 6. Department of Neurology, Boston Children's Hospital, United States. Electronic address: Janet.Soul@childrens.harvard.edu.
Abstract
BACKGROUND: While therapeutic hypothermia (TH) is an effective neuroprotective therapy for neonatal hypoxic-ischemic encephalopathy, TH has not been demonstrated to improve outcome in other pediatric populations. Patients with acquired or congenital heart disease (CHD) are at high risk of both cardiac arrest and neurodevelopmental impairments, and therapies are needed to improve neurologic outcome. The primary goal of our study was to compare safety/efficacy outcomes in post-arrest CHD patients treated with TH versus controls not treated with TH. METHODS: Patients with CHD treated during the first 18 months after initiation of a post-arrest TH protocol (temperature goal: 33.5 °C) were compared to historical and contemporary post-arrest controls not treated with TH. Post-arrest data, including temperature, safety measures (e.g. arrhythmia, bleeding), neurodiagnostic data (EEG, neuroimaging), and survival were compared. RESULTS: Thirty arrest episodes treated with TH and 51 control arrest episodes were included. The groups did not differ in age, duration of arrest, post-arrest lactate, or use of ECMO-CPR. The TH group's post-arrest temperature was significantly lower than control's (33.6 ± 0.2 °C vs 34.7 ± 0.5 °C, p < 0.001). There was no difference between the groups in safety/efficacy measures, including arrhythmia, infections, chest-tube output, or neuroimaging abnormalities, nor in hospital survival (TH 61.5% vs control 59.1%, p = NS). Significantly more controls had seizures than TH patients (26.1% vs. 4.0%, p = 0.04). Almost all seizures were subclinical and occurred more than 24 h post-arrest. CONCLUSION: Our data show that pediatric CHD patients who suffer cardiac arrest can be treated effectively and safely with TH, which may decrease the incidence of seizures.
BACKGROUND: While therapeutic hypothermia (TH) is an effective neuroprotective therapy for neonatal hypoxic-ischemicencephalopathy, TH has not been demonstrated to improve outcome in other pediatric populations. Patients with acquired or congenital heart disease (CHD) are at high risk of both cardiac arrest and neurodevelopmental impairments, and therapies are needed to improve neurologic outcome. The primary goal of our study was to compare safety/efficacy outcomes in post-arrest CHDpatients treated with TH versus controls not treated with TH. METHODS:Patients with CHD treated during the first 18 months after initiation of a post-arrest TH protocol (temperature goal: 33.5 °C) were compared to historical and contemporary post-arrest controls not treated with TH. Post-arrest data, including temperature, safety measures (e.g. arrhythmia, bleeding), neurodiagnostic data (EEG, neuroimaging), and survival were compared. RESULTS: Thirty arrest episodes treated with TH and 51 control arrest episodes were included. The groups did not differ in age, duration of arrest, post-arrest lactate, or use of ECMO-CPR. The TH group's post-arrest temperature was significantly lower than control's (33.6 ± 0.2 °C vs 34.7 ± 0.5 °C, p < 0.001). There was no difference between the groups in safety/efficacy measures, including arrhythmia, infections, chest-tube output, or neuroimaging abnormalities, nor in hospital survival (TH 61.5% vs control 59.1%, p = NS). Significantly more controls had seizures than TH patients (26.1% vs. 4.0%, p = 0.04). Almost all seizures were subclinical and occurred more than 24 h post-arrest. CONCLUSION: Our data show that pediatric CHD patients who suffer cardiac arrest can be treated effectively and safely with TH, which may decrease the incidence of seizures.
Authors: Renée A Shellhaas; Taeun Chang; Tammy Tsuchida; Mark S Scher; James J Riviello; Nicholas S Abend; Sylvie Nguyen; Courtney J Wusthoff; Robert R Clancy Journal: J Clin Neurophysiol Date: 2011-12 Impact factor: 2.177
Authors: Susan E Jacobs; Colin J Morley; Terrie E Inder; Michael J Stewart; Katherine R Smith; Patrick J McNamara; Ian M R Wright; Haresh M Kirpalani; Brian A Darlow; Lex W Doyle Journal: Arch Pediatr Adolesc Med Date: 2011-04-04
Authors: Dorothea J Eicher; Carol L Wagner; Lakshmi P Katikaneni; Thomas C Hulsey; W Thomas Bass; David A Kaufman; Michael J Horgan; Sheila Languani; Jatinder J Bhatia; Lawrence M Givelichian; Koravangatta Sankaran; Jerome Y Yager Journal: Pediatr Neurol Date: 2005-01 Impact factor: 3.372
Authors: Seetha Shankaran; Abbot R Laptook; Richard A Ehrenkranz; Jon E Tyson; Scott A McDonald; Edward F Donovan; Avroy A Fanaroff; W Kenneth Poole; Linda L Wright; Rosemary D Higgins; Neil N Finer; Waldemar A Carlo; Shahnaz Duara; William Oh; C Michael Cotten; David K Stevenson; Barbara J Stoll; James A Lemons; Ronnie Guillet; Alan H Jobe Journal: N Engl J Med Date: 2005-10-13 Impact factor: 91.245
Authors: Alexis A Topjian; Sarah M Sánchez; Justine Shults; Robert A Berg; Dennis J Dlugos; Nicholas S Abend Journal: Pediatr Crit Care Med Date: 2016-06 Impact factor: 3.624
Authors: N S Abend; A Topjian; R Ichord; S T Herman; M Helfaer; M Donnelly; V Nadkarni; D J Dlugos; R R Clancy Journal: Neurology Date: 2009-06-02 Impact factor: 9.910
Authors: J William Gaynor; Gail P Jarvik; Marsha Gerdes; Daniel S Kim; Ramakrishnan Rajagopalan; Judy Bernbaum; Gil Wernovsky; Susan C Nicolson; Thomas L Spray; Robert R Clancy Journal: J Thorac Cardiovasc Surg Date: 2013-07 Impact factor: 5.209
Authors: Peter D Gluckman; John S Wyatt; Denis Azzopardi; Roberta Ballard; A David Edwards; Donna M Ferriero; Richard A Polin; Charlene M Robertson; Marianne Thoresen; Andrew Whitelaw; Alistair J Gunn Journal: Lancet Date: 2005 Feb 19-25 Impact factor: 79.321
Authors: Frank W Moler; Faye S Silverstein; Richard Holubkov; Beth S Slomine; James R Christensen; Vinay M Nadkarni; Kathleen L Meert; Amy E Clark; Brittan Browning; Victoria L Pemberton; Kent Page; Seetha Shankaran; Jamie S Hutchison; Christopher J L Newth; Kimberly S Bennett; John T Berger; Alexis Topjian; Jose A Pineda; Joshua D Koch; Charles L Schleien; Heidi J Dalton; George Ofori-Amanfo; Denise M Goodman; Ericka L Fink; Patrick McQuillen; Jerry J Zimmerman; Neal J Thomas; Elise W van der Jagt; Melissa B Porter; Michael T Meyer; Rick Harrison; Nga Pham; Adam J Schwarz; Jeffrey E Nowak; Jeffrey Alten; Derek S Wheeler; Utpal S Bhalala; Karen Lidsky; Eric Lloyd; Mudit Mathur; Samir Shah; Theodore Wu; Andreas A Theodorou; Ronald C Sanders; J Michael Dean Journal: N Engl J Med Date: 2015-04-25 Impact factor: 91.245
Authors: Wojciech Wieczorek; Jarosław Meyer-Szary; Milosz J Jaguszewski; Krzysztof J Filipiak; Maciej Cyran; Jacek Smereka; Aleksandra Gasecka; Kurt Ruetzler; Lukasz Szarpak Journal: J Clin Med Date: 2021-03-30 Impact factor: 4.241